Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1996 4
1997 2
1998 5
1999 13
2000 8
2001 15
2002 8
2003 21
2004 18
2005 21
2006 31
2007 39
2008 44
2009 78
2010 113
2011 134
2012 140
2013 142
2014 144
2015 112
2016 136
2017 132
2018 124
2019 123
2020 116
2021 104
2022 78
2023 90
2024 38

Text availability

Article attribute

Article type

Publication date

Search Results

1,723 results

Results by year

Filters applied: . Clear all
Page 1
Use of plerixafor to mobilize haematopoietic progenitor cells in healthy donors.
Romon I, Castillo C, Cid J, Lozano M. Romon I, et al. Vox Sang. 2022 Jan;117(1):6-16. doi: 10.1111/vox.13175. Epub 2021 Jun 23. Vox Sang. 2022. PMID: 34159611 Review.
Plerixafor has also been used as a sole mobilization agent. Plerixafor alone or coupled with G-CSF might lead to harvesting distinct cellular populations conferring improved engraftment properties and increased survival. Those characteristics might make plerixafo …
Plerixafor has also been used as a sole mobilization agent. Plerixafor alone or coupled with G-CSF might lead to harvesting di …
Plerixafor for stem cell mobilization: the current status.
Bilgin YM, de Greef GE. Bilgin YM, et al. Curr Opin Hematol. 2016 Jan;23(1):67-71. doi: 10.1097/MOH.0000000000000200. Curr Opin Hematol. 2016. PMID: 26554889 Review.
We discussed in this review the current status of the optimal use of plerixafor in different clinical diagnoses and settings. RECENT FINDINGS: Plerixafor seems to be more effective in patients with multiple myeloma than in lymphoma. ...Plerixafor is well tole …
We discussed in this review the current status of the optimal use of plerixafor in different clinical diagnoses and settings. RECENT …
Plerixafor: what we still have to learn.
Lanza F, Gardellini A, Laszlo D, Martino M. Lanza F, et al. Expert Opin Biol Ther. 2015 Feb;15(2):143-7. doi: 10.1517/14712598.2015.971750. Epub 2014 Oct 15. Expert Opin Biol Ther. 2015. PMID: 25315706
Plerixafor, a hematopoietic stem cell mobilizer, is indicated in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. Curre …
Plerixafor, a hematopoietic stem cell mobilizer, is indicated in combination with G-CSF to mobilize hematopoietic stem cells to the p …
Plerixafor on a WHIM - Promise or Fantasy of a New CXCR4 Inhibitor for This Rare, but Important Syndrome?
Merati N, Sivachandran S, Jfri A, Ben-Shoshan M, Vinh DC, Popradi G, Litvinov IV. Merati N, et al. Skin Therapy Lett. 2022 Mar;27(2):1-5. Skin Therapy Lett. 2022. PMID: 35385630 Free article. Review.
Research demonstrated that truncating gain-of-function mutations of the C-X-C chemokine receptor type 4 gene (CXCR4) are responsible for this disease. Plerixafor, a specific small molecule antagonist of CXCR4, is currently used for peripheral blood hematopoietic stem cell …
Research demonstrated that truncating gain-of-function mutations of the C-X-C chemokine receptor type 4 gene (CXCR4) are responsible for thi …
Plerixafor.
DiPersio JF, Uy GL, Yasothan U, Kirkpatrick P. DiPersio JF, et al. Nat Rev Drug Discov. 2009 Feb;8(2):105-6. doi: 10.1038/nrd2819. Nat Rev Drug Discov. 2009. PMID: 19180104 No abstract available.
Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.
Jantunen E, Varmavuo V, Valtola J. Jantunen E, et al. Expert Rev Hematol. 2016 Aug;9(8):723-32. doi: 10.1080/17474086.2016.1208082. Epub 2016 Jul 15. Expert Rev Hematol. 2016. PMID: 27355397 Review.
AREAS COVERED: The available phase II and III data on plerixafor has been reviewed. The efficacy of plerixafor in the mobilization of CD34(+) cells in predicted poor mobilizers as well as in patients who had failed a mobilization has been evaluated. The pre-emptive …
AREAS COVERED: The available phase II and III data on plerixafor has been reviewed. The efficacy of plerixafor in the mobiliza …
Plerixafor for mobilization of blood stem cells in autologous transplantation: an update.
Jantunen E, Varmavuo V. Jantunen E, et al. Expert Opin Biol Ther. 2014 Jun;14(6):851-61. doi: 10.1517/14712598.2014.902927. Epub 2014 Mar 27. Expert Opin Biol Ther. 2014. PMID: 24673120 Review.
G-CSF alone or combined with chemotherapy have been used to mobilize CD34(+) cells. Plerixafor is a novel drug used for mobilization purposes. AREAS COVERED: We have evaluated recent data in regard to plerixafor use in predicted or proven poor mobilizers. ...EXPERT …
G-CSF alone or combined with chemotherapy have been used to mobilize CD34(+) cells. Plerixafor is a novel drug used for mobilization …
Mozobil (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration.
De Clercq E. De Clercq E. Antivir Chem Chemother. 2019 Jan-Dec;27:2040206619829382. doi: 10.1177/2040206619829382. Antivir Chem Chemother. 2019. PMID: 30776910 Free PMC article. Review.
AMD3100 (plerixafor, Mozobil) was first identified as an anti-HIV agent specifically active against the T4-lymphotropic HIV strains, as it selectively blocked the CXCR4 receptor. ...
AMD3100 (plerixafor, Mozobil) was first identified as an anti-HIV agent specifically active against the T4-lymphotropic HIV strains, …
Plerixafor: a peripheral blood stem cell mobilizer.
Kessans MR, Gatesman ML, Kockler DR. Kessans MR, et al. Pharmacotherapy. 2010 May;30(5):485-92. doi: 10.1592/phco.30.5.485. Pharmacotherapy. 2010. PMID: 20411999 Review.
Plerixafor has also shown promising results in small studies enrolling patients with Hodgkin's lymphoma. ...Overall, plerixafor has been generally well tolerated with adverse effects classified as mild to moderate. ...
Plerixafor has also shown promising results in small studies enrolling patients with Hodgkin's lymphoma. ...Overall, plerixafor …
Plerixafor (Mozobil) and other mobilizing agents.
Pierelli L, Perseghin P. Pierelli L, et al. Transfus Apher Sci. 2013 Apr;48(2):133-5. doi: 10.1016/j.transci.2013.02.005. Epub 2013 Apr 9. Transfus Apher Sci. 2013. PMID: 23582743 Review. No abstract available.
1,723 results

Searches related to "plerixafor"